Identification

Name
Etacrynic acid
Accession Number
DB00903  (APRD00251)
Type
Small Molecule
Groups
Approved
Description

A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.

Structure
Thumb
Synonyms
  • (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid
  • acide étacrynique
  • ácido etacrínico
  • acidum etacrynicum
  • Etacrinic acid
  • Etakrinic acid
  • Ethacryinic Acid
  • Ethacrynate
  • Ethacrynic acid
  • Methylenebutyrylphenoxyacetic acid
External IDs
MK-595 / NSC-85791
Product Ingredients
IngredientUNIICASInChI Key
Ethacrynate sodiumK41MYV7MPM6500-81-8CWCSCNSKBSCYCS-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EdecrinTablet25 mg/1OralKaiser Foundations Hospitals2013-01-10Not applicableUs25010 0215 15 nlmimage10 a93ad486
EdecrinTablet25 mg/1OralAvera Mc Kennan Hospital2015-10-02Not applicableUs
EdecrinTablet25 mgOralValeant Canada Lp Valeant Canada S.E.C.2004-10-15Not applicableCanada
EdecrinTablet25 mg/1OralAton Pharma, Inc.1967-01-10Not applicableUs
Edecrin Tab 50mgTablet50 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1968-12-312004-03-04Canada
Ethacrynate Sodium for Injection USPPowder, for solution50 mgIntravenousSterimax IncNot applicableNot applicableCanada
Ethacrynic AcidTablet25 mg/1OralOceanside Pharmaceuticals1967-01-10Not applicableUs
Ethacrynic SodiumPowder, for solution50 mg/50mLIntravenousOceanside Pharmaceuticals1967-01-10Not applicableUs
Sodium EdecrinPowder, for solution50 mg/50mLIntravenousAton Pharma, Inc.1967-01-10Not applicableUs
Sodium EdecrinPowder, for solution50 mgIntravenousValeant Canada Lp Valeant Canada S.E.C.1968-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethacrynate SodiumInjection, powder, for solution50 mg/50mLIntravenousPar Pharmaceutical2015-07-30Not applicableUs
Ethacrynic AcidTablet25 mg/1OralEdenbridge Pharmaceuticals Llc2016-07-05Not applicableUs
Ethacrynic AcidTablet25 mg/1OralGolden State Medical Supply2017-05-04Not applicableUs
Ethacrynic AcidTablet25 mg/1OralPar Pharmaceutical2017-07-21Not applicableUs
Ethacrynic AcidTablet25 mg/1OralIngenus Pharmaceuticals Nj, Llc2016-07-05Not applicableUs
Ethacrynic AcidTablet25 mg/1OralWest Ward Pharmaceutical2017-02-24Not applicableUs
Ethacrynic SodiumInjection, powder, lyophilized, for solution50 mg/50mLIntravenousMylan Institutional2016-08-31Not applicableUs
Vpi-ethacrynate SodiumPowder, for solution50 mgIntravenousVpi Pharmaceuticals IncNot applicableNot applicableCanada
International/Other Brands
Crinuryl (Assia) / Edecril (Merck) / Edecrina / Endecril / Hidromedin / Hydromedin (Merck) / Mingit / Otacril / Reomax (Bioindustria) / Taladren (Malesci) / Uregit
Categories
UNII
M5DP350VZV
CAS number
58-54-8
Weight
Average: 303.138
Monoisotopic: 302.011264286
Chemical Formula
C13H12Cl2O4
InChI Key
AVOLMBLBETYQHX-UHFFFAOYSA-N
InChI
InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
IUPAC Name
2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
SMILES
CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1

Pharmacology

Indication

For the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.

Structured Indications
Pharmacodynamics

Ethacrynic acid is a monosulfonamyl loop or high ceiling diuretic. Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynic acid inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynic acid is effective in many patients who have significant degrees of renal insufficiency. Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis.

Mechanism of action

Ethacrynic acid inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. Diuretics also lower blood pressure initially by reducing plasma and extracellular fluid volume; cardiac output also decreases, explaining its antihypertensive action. Eventually, cardiac output returns to normal with an accompanying decrease in peripheral resistance. Its mode of action does not involve carbonic anhydrase inhibition.

TargetActionsOrganism
ASolute carrier family 12 member 1
inhibitor
Human
ASodium/potassium-transporting ATPase subunit alpha-1
inhibitor
Human
ULymphoid enhancer-binding factor 1Not AvailableHuman
UGlutathione S-transferase P
inhibitor
Human
Absorption

Onset of action is rapid, usually within 30 minutes after an oral dose of ethacrynic acid or within 5 minutes after an intravenous injection of ethacrynic acid.

Volume of distribution
Not Available
Protein binding

> 98%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Overdosage may lead to excessive diuresis with electrolyte depletion.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ethacrynic Acid Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Etacrynic acid.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Etacrynic acid.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Etacrynic acid.Experimental, Illicit
AceclofenacAceclofenac may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
AcemetacinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Etacrynic acid.Approved
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
AclarubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aclarubicin.Investigational
AdapaleneAdapalene may decrease the diuretic activities of Etacrynic acid.Approved
AlclofenacAlclofenac may decrease the diuretic activities of Etacrynic acid.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Etacrynic acid.Approved
AlcuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Alcuronium.Experimental
AldosteroneAldosterone may increase the hypokalemic activities of Etacrynic acid.Experimental, Investigational
AldoxorubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aldoxorubicin.Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Etacrynic acid.Approved, Illicit
AllopurinolThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Allopurinol.Approved
AlminoprofenAlminoprofen may decrease the diuretic activities of Etacrynic acid.Experimental
AloxiprinAloxiprin may decrease the diuretic activities of Etacrynic acid.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Etacrynic acid.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Etacrynic acid.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Etacrynic acid.Approved
AmikacinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amikacin.Approved, Vet Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Etacrynic acid.Approved
AmrubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amrubicin.Approved, Investigational
AndrographolideAndrographolide may decrease the diuretic activities of Etacrynic acid.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Etacrynic acid.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Etacrynic acid.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Etacrynic acid.Investigational
AnisodamineAnisodamine may decrease the diuretic activities of Etacrynic acid.Investigational
AnnamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Annamycin.Investigational
AntipyrineAntipyrine may decrease the diuretic activities of Etacrynic acid.Approved
ApocyninApocynin may decrease the diuretic activities of Etacrynic acid.Investigational
ApramycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Apramycin.Experimental, Vet Approved
ApremilastApremilast may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Arbekacin.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Etacrynic acid.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Etacrynic acid.Investigational
AtracuriumEtacrynic acid may decrease the neuromuscular blocking activities of Atracurium.Experimental, Investigational
Atracurium besylateEtacrynic acid may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the diuretic activities of Etacrynic acid.Withdrawn
AzelastineAzelastine may decrease the diuretic activities of Etacrynic acid.Approved
BalsalazideBalsalazide may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
BekanamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bekanamycin.Experimental
BenazeprilEtacrynic acid may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacBendazac may decrease the diuretic activities of Etacrynic acid.Experimental
BenorilateBenorilate may decrease the diuretic activities of Etacrynic acid.Experimental
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Etacrynic acid.Withdrawn
BenzydamineBenzydamine may decrease the diuretic activities of Etacrynic acid.Approved
BetamethasoneBetamethasone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
BevoniumBevonium may decrease the diuretic activities of Etacrynic acid.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Etacrynic acid.Experimental, Illicit, Withdrawn
BromfenacBromfenac may decrease the diuretic activities of Etacrynic acid.Approved
BucillamineBucillamine may decrease the diuretic activities of Etacrynic acid.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Etacrynic acid.Approved
BufexamacBufexamac may decrease the diuretic activities of Etacrynic acid.Experimental
BumadizoneBumadizone may decrease the diuretic activities of Etacrynic acid.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Etacrynic acid.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etacrynic acid.Approved, Illicit, Vet Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Etacrynic acid.Approved
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Etacrynic acid.Approved
CandoxatrilEtacrynic acid may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilEtacrynic acid may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the diuretic activities of Etacrynic acid.Experimental, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Etacrynic acid.Illicit, Investigational, Vet Approved
CarprofenCarprofen may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the diuretic activities of Etacrynic acid.Experimental
CelecoxibCelecoxib may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
ChloroquineChloroquine may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the diuretic activities of Etacrynic acid.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
CilazaprilEtacrynic acid may increase the hypotensive activities of Cilazapril.Approved
CisatracuriumEtacrynic acid may decrease the neuromuscular blocking activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateEtacrynic acid may decrease the neuromuscular blocking activities of Cisatracurium besylate.Approved
CisplatinEtacrynic acid may increase the nephrotoxic activities of Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Etacrynic acid.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Etacrynic acid.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Etacrynic acid.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Etacrynic acid.Approved
ClonixinClonixin may decrease the diuretic activities of Etacrynic acid.Approved
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Etacrynic acid.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Etacrynic acid.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Etacrynic acid.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Etacrynic acid.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Etacrynic acid.Approved
CurcuminCurcumin may decrease the diuretic activities of Etacrynic acid.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cymarin.Experimental
DaunorubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Daunorubicin.Approved
DecamethoniumEtacrynic acid may decrease the neuromuscular blocking activities of Decamethonium.Approved
DeflazacortDeflazacort may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
DelaprilEtacrynic acid may increase the hypotensive activities of Delapril.Experimental
DersalazineDersalazine may decrease the diuretic activities of Etacrynic acid.Investigational
DeslanosideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Etacrynic acid.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Etacrynic acid.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Etacrynic acid.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Etacrynic acid.Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Etacrynic acid.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etacrynic acid.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Etacrynic acid.Approved, Investigational
DibekacinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dibekacin.Experimental
DiclofenacDiclofenac may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Etacrynic acid.Approved
DifenpiramideDifenpiramide may decrease the diuretic activities of Etacrynic acid.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Etacrynic acid.Approved
DiflunisalDiflunisal may decrease the diuretic activities of Etacrynic acid.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hypokalemic activities of Etacrynic acid.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etacrynic acid.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etacrynic acid.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etacrynic acid.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Etacrynic acid.Experimental
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etacrynic acid.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Etacrynic acid.Approved
DobutamineDobutamine may increase the hypokalemic activities of Etacrynic acid.Approved
DofetilideEtacrynic acid may increase the QTc-prolonging activities of Dofetilide.Approved
Domoic AcidEtacrynic acid may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chlorideEtacrynic acid may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Doxorubicin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Etacrynic acid.Experimental
DroxicamDroxicam may decrease the diuretic activities of Etacrynic acid.Withdrawn
DroxidopaDroxidopa may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
DuvelisibDuvelisib may decrease the diuretic activities of Etacrynic acid.Investigational
E-6201E-6201 may decrease the diuretic activities of Etacrynic acid.Investigational
EnalaprilEtacrynic acid may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatEtacrynic acid may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Etacrynic acid.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
EpirizoleEpirizole may decrease the diuretic activities of Etacrynic acid.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Epirubicin.Approved
EquileninEquilenin may increase the hypokalemic activities of Etacrynic acid.Experimental
EquilinEquilin may increase the hypokalemic activities of Etacrynic acid.Approved
EstroneEstrone may increase the hypokalemic activities of Etacrynic acid.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptEtanercept may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
EthenzamideEthenzamide may decrease the diuretic activities of Etacrynic acid.Experimental
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Etacrynic acid.Withdrawn
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etacrynic acid.Approved, Illicit
EtodolacEtodolac may decrease the diuretic activities of Etacrynic acid.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
EtoricoxibEtoricoxib may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Etacrynic acid.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
ExisulindExisulind may decrease the diuretic activities of Etacrynic acid.Investigational
FelbinacFelbinac may decrease the diuretic activities of Etacrynic acid.Experimental
FenbufenFenbufen may decrease the diuretic activities of Etacrynic acid.Approved
FenoprofenFenoprofen may decrease the diuretic activities of Etacrynic acid.Approved
FenoterolFenoterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etacrynic acid.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the diuretic activities of Etacrynic acid.Experimental
FeprazoneFeprazone may decrease the diuretic activities of Etacrynic acid.Experimental
Ferulic acidFerulic acid may decrease the diuretic activities of Etacrynic acid.Experimental
FloctafenineFloctafenine may decrease the diuretic activities of Etacrynic acid.Approved, Withdrawn
FluasteroneFluasterone may increase the hypokalemic activities of Etacrynic acid.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Etacrynic acid.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Etacrynic acid.Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FlunixinFlunixin may decrease the diuretic activities of Etacrynic acid.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the diuretic activities of Etacrynic acid.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Etacrynic acid.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Etacrynic acid.Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Etacrynic acid.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Etacrynic acid.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Etacrynic acid.Approved
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Etacrynic acid.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Etacrynic acid.Approved
FormestaneFormestane may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Etacrynic acid.Approved
FosinoprilEtacrynic acid may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Etacrynic acid.Approved
FramycetinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Framycetin.Approved
FurosemideFurosemide may increase the ototoxic activities of Etacrynic acid.Approved, Vet Approved
GallamineEtacrynic acid may decrease the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideEtacrynic acid may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with GENTAMICIN C1A.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Gitoformate.Experimental
GPX-150The risk or severity of adverse effects can be increased when Etacrynic acid is combined with GPX-150.Investigational
GuacetisalGuacetisal may decrease the diuretic activities of Etacrynic acid.Experimental
HalcinonideHalcinonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Withdrawn
HE3286HE3286 may increase the hypokalemic activities of Etacrynic acid.Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the diuretic activities of Etacrynic acid.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Etacrynic acid.Approved, Illicit, Investigational
HigenamineHigenamine may decrease the diuretic activities of Etacrynic acid.Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etacrynic acid.Approved, Illicit
Hygromycin BThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hygromycin B.Vet Approved
IbuprofenIbuprofen may decrease the diuretic activities of Etacrynic acid.Approved
IbuproxamIbuproxam may decrease the diuretic activities of Etacrynic acid.Withdrawn
IcatibantIcatibant may decrease the diuretic activities of Etacrynic acid.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Idarubicin.Approved
ImidaprilEtacrynic acid may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the diuretic activities of Etacrynic acid.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Etacrynic acid.Approved
IndobufenIndobufen may decrease the diuretic activities of Etacrynic acid.Investigational
IndomethacinIndomethacin may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
IndoprofenIndoprofen may decrease the diuretic activities of Etacrynic acid.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isepamicin.Experimental
IsoetarineIsoetarine may increase the hypokalemic activities of Etacrynic acid.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Etacrynic acid.Approved
IsoxicamIsoxicam may decrease the diuretic activities of Etacrynic acid.Withdrawn
IstaroximeIstaroxime may increase the hypokalemic activities of Etacrynic acid.Investigational
IvabradineEtacrynic acid may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneKebuzone may decrease the diuretic activities of Etacrynic acid.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etacrynic acid.Approved, Investigational
KetoprofenKetoprofen may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
KetorolacKetorolac may decrease the diuretic activities of Etacrynic acid.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etacrynic acid.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etacrynic acid.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Etacrynic acid.Approved
LicoriceLicorice may increase the hypokalemic activities of Etacrynic acid.Approved
LisinoprilEtacrynic acid may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the diuretic activities of Etacrynic acid.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Etacrynic acid.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Etacrynic acid.Illicit
LonazolacLonazolac may decrease the diuretic activities of Etacrynic acid.Experimental
LornoxicamLornoxicam may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
LoteprednolLoteprednol may increase the hypokalemic activities of Etacrynic acid.Approved
LoxoprofenLoxoprofen may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
LumiracoxibLumiracoxib may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Etacrynic acid.Approved
MasoprocolMasoprocol may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Etacrynic acid.Investigational
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Etacrynic acid.Approved
Mefenamic acidMefenamic acid may decrease the diuretic activities of Etacrynic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Etacrynic acid.Vet Approved
MeloxicamMeloxicam may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Etacrynic acid.Experimental
MesalazineMesalazine may decrease the diuretic activities of Etacrynic acid.Approved
MetamizoleMetamizole may decrease the diuretic activities of Etacrynic acid.Investigational, Withdrawn
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Etacrynic acid.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Etacrynic acid.Approved, Illicit
MethotrexateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methotrexate.Approved
Methyl salicylateMethyl salicylate may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metildigoxin.Experimental
MetocurineEtacrynic acid may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideEtacrynic acid may decrease the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetrizamideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metrizamide.Approved
MicronomicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Micronomicin.Experimental
MivacuriumEtacrynic acid may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineMizoribine may decrease the diuretic activities of Etacrynic acid.Investigational
MoexiprilEtacrynic acid may increase the hypotensive activities of Moexipril.Approved
MofebutazoneMofebutazone may decrease the diuretic activities of Etacrynic acid.Experimental
MometasoneMometasone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Etacrynic acid.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Etacrynic acid.Approved
NabumetoneNabumetone may decrease the diuretic activities of Etacrynic acid.Approved
NafamostatNafamostat may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
NaftifineNaftifine may decrease the diuretic activities of Etacrynic acid.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etacrynic acid.Approved
NaproxenNaproxen may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
NCX 1022NCX 1022 may increase the hypokalemic activities of Etacrynic acid.Investigational
NeamineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Neamine.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinEtacrynic acid may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the diuretic activities of Etacrynic acid.Approved
NetilmicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Netilmicin.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Etacrynic acid.Experimental
NifenazoneNifenazone may decrease the diuretic activities of Etacrynic acid.Experimental
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Etacrynic acid.Approved
NimesulideNimesulide may decrease the diuretic activities of Etacrynic acid.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the diuretic activities of Etacrynic acid.Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Etacrynic acid.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Etacrynic acid.Approved, Illicit
OleandrinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Etacrynic acid.Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Etacrynic acid.Approved
OlopatadineOlopatadine may decrease the diuretic activities of Etacrynic acid.Approved
OlsalazineOlsalazine may decrease the diuretic activities of Etacrynic acid.Approved
OmapatrilatEtacrynic acid may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Etacrynic acid.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Etacrynic acid.Approved
OrgoteinOrgotein may decrease the diuretic activities of Etacrynic acid.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ouabain.Approved
OxaprozinOxaprozin may decrease the diuretic activities of Etacrynic acid.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etacrynic acid.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etacrynic acid.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Etacrynic acid.Approved, Withdrawn
PancuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Etacrynic acid.Approved
ParecoxibParecoxib may decrease the diuretic activities of Etacrynic acid.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paromomycin.Approved, Investigational
ParthenolideParthenolide may decrease the diuretic activities of Etacrynic acid.Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etacrynic acid.Approved, Vet Approved
PerindoprilEtacrynic acid may increase the hypotensive activities of Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etacrynic acid.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Etacrynic acid.Experimental
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Etacrynic acid.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Etacrynic acid.Experimental
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Etacrynic acid.Approved, Investigational
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
PipecuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pirarubicin.Investigational
PirbuterolPirbuterol may increase the hypokalemic activities of Etacrynic acid.Approved
PirfenidonePirfenidone may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Etacrynic acid.Investigational
PiroxicamPiroxicam may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
PirprofenPirprofen may decrease the diuretic activities of Etacrynic acid.Experimental
PlazomicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Plazomicin.Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Plicamycin.Approved, Investigational, Withdrawn
PranoprofenPranoprofen may decrease the diuretic activities of Etacrynic acid.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Etacrynic acid.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Etacrynic acid.Investigational
PrednicarbatePrednicarbate may increase the hypokalemic activities of Etacrynic acid.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Etacrynic acid.Experimental, Investigational
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Etacrynic acid.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
ProglumetacinProglumetacin may decrease the diuretic activities of Etacrynic acid.Experimental
PropacetamolPropacetamol may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
PropyphenazonePropyphenazone may decrease the diuretic activities of Etacrynic acid.Experimental
ProquazoneProquazone may decrease the diuretic activities of Etacrynic acid.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Proscillaridin.Experimental
PTC299PTC299 may decrease the diuretic activities of Etacrynic acid.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Puromycin.Experimental
PyrantelEtacrynic acid may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinaprilEtacrynic acid may increase the hypotensive activities of Quinapril.Approved, Investigational
RamiprilEtacrynic acid may increase the hypotensive activities of Ramipril.Approved
RapacuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etacrynic acid.Approved
RescinnamineEtacrynic acid may increase the hypotensive activities of Rescinnamine.Approved
ResveratrolResveratrol may decrease the diuretic activities of Etacrynic acid.Approved, Experimental, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ribostamycin.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Etacrynic acid.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
RocuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the diuretic activities of Etacrynic acid.Investigational, Withdrawn
SabarubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sabarubicin.Investigational
SalbutamolSalbutamol may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
SalicylamideSalicylamide may decrease the diuretic activities of Etacrynic acid.Approved
Salicylic acidSalicylic acid may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Etacrynic acid.Approved
SalsalateSalsalate may decrease the diuretic activities of Etacrynic acid.Approved
SemapimodSemapimod may decrease the diuretic activities of Etacrynic acid.Investigational
SeratrodastSeratrodast may decrease the diuretic activities of Etacrynic acid.Approved
SerrapeptaseSerrapeptase may decrease the diuretic activities of Etacrynic acid.Investigational
SisomicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sisomicin.Investigational
Sodium phosphateEtacrynic acid may increase the nephrotoxic activities of Sodium phosphate.Approved
SP1049CThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with SP1049C.Investigational
SpectinomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Spectinomycin.Approved, Investigational, Vet Approved
SpiraprilEtacrynic acid may increase the hypotensive activities of Spirapril.Approved
SRT501SRT501 may decrease the diuretic activities of Etacrynic acid.Investigational
StreptomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Streptomycin.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Streptozocin.Approved
SuccinylcholineEtacrynic acid may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etacrynic acid.Approved, Investigational
SulfasalazineSulfasalazine may decrease the diuretic activities of Etacrynic acid.Approved
SulindacSulindac may decrease the diuretic activities of Etacrynic acid.Approved
SulpirideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sulpiride.Approved, Investigational
SuprofenSuprofen may decrease the diuretic activities of Etacrynic acid.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the diuretic activities of Etacrynic acid.Experimental
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Etacrynic acid.Approved
TarenflurbilTarenflurbil may decrease the diuretic activities of Etacrynic acid.Investigational
TemocaprilEtacrynic acid may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the diuretic activities of Etacrynic acid.Experimental
TenoxicamTenoxicam may decrease the diuretic activities of Etacrynic acid.Approved
TepoxalinTepoxalin may decrease the diuretic activities of Etacrynic acid.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Etacrynic acid.Approved
TeriflunomideTeriflunomide may decrease the diuretic activities of Etacrynic acid.Approved
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Etacrynic acid.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Etacrynic acid.Experimental
TinoridineTinoridine may decrease the diuretic activities of Etacrynic acid.Investigational
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Etacrynic acid.Experimental
TixocortolTixocortol may increase the hypokalemic activities of Etacrynic acid.Approved, Withdrawn
TobramycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tobramycin.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Etacrynic acid.Approved
TolmetinTolmetin may decrease the diuretic activities of Etacrynic acid.Approved
TopiramateEtacrynic acid may increase the hypokalemic activities of Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid.Approved, Investigational
TrandolaprilEtacrynic acid may increase the hypotensive activities of Trandolapril.Approved
TranilastTranilast may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
TribenosideTribenoside may decrease the diuretic activities of Etacrynic acid.Experimental
TriptolideTriptolide may decrease the diuretic activities of Etacrynic acid.Investigational
Trolamine salicylateTrolamine salicylate may decrease the diuretic activities of Etacrynic acid.Approved
TubocurarineEtacrynic acid may decrease the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolUlobetasol may increase the hypokalemic activities of Etacrynic acid.Approved
ValdecoxibValdecoxib may decrease the diuretic activities of Etacrynic acid.Investigational, Withdrawn
ValrubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Valrubicin.Approved
VecuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Vecuronium.Approved
VilanterolVilanterol may increase the hypokalemic activities of Etacrynic acid.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Etacrynic acid.Approved
ZaltoprofenZaltoprofen may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
ZileutonZileuton may decrease the diuretic activities of Etacrynic acid.Approved, Investigational, Withdrawn
ZofenoprilEtacrynic acid may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the diuretic activities of Etacrynic acid.Withdrawn
Zoptarelin doxorubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Zoptarelin doxorubicin.Investigational
ZorubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Zorubicin.Experimental
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference

Schultz, E.M. and Sprague, J.M.; U.S. Patent 3,255,241; June 7, 1966; assigned to Merck & co., Inc.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015039
KEGG Drug
D00313
PubChem Compound
3278
PubChem Substance
46507562
ChemSpider
3163
BindingDB
50186231
ChEBI
4876
ChEMBL
CHEMBL456
Therapeutic Targets Database
DAP000748
PharmGKB
PA449518
HET
EAA
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ethacrynic_acid
ATC Codes
C03CC01 — Etacrynic acid
AHFS Codes
  • 40:28.08 — Loop Diuretics
PDB Entries
11gs / 1gse / 1gsf / 2gss / 3dgq / 3gss / 3hjo / 3km6 / 3kmo / 3n9j
FDA label
Download (75.2 KB)
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentBladder Cancers1
1, 2CompletedOtherGlaucoma1
3CompletedTreatmentFluid Overload1

Pharmacoeconomics

Manufacturers
  • Aton pharma inc
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg
TabletOral25 mg/1
TabletOral50 mg
Injection, powder, for solutionIntravenous50 mg/50mL
Injection, powder, lyophilized, for solutionIntravenous50 mg/50mL
Powder, for solutionIntravenous50 mg/50mL
Powder, for solutionIntravenous50 mg
Prices
Unit descriptionCostUnit
Sodium edecrin 50 mg vial527.4USD vial
Edecrin sodium 50 mg vial114.0USD vial
Ethacrynic acid 100% powder26.4USD g
Edecrin 25 mg tablet3.19USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)118.5-120.5Schultz, E.M. and Sprague, J.M.; U.S. Patent 3,255,241; June 7, 1966; assigned to Merck & co., Inc.
logP3.3Not Available
pKa3.5MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility0.0194 mg/mLALOGPS
logP3.42ALOGPS
logP3.66ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)2.8ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.6 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity72.22 m3·mol-1ChemAxon
Polarizability28.57 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9591
Blood Brain Barrier-0.6921
Caco-2 permeable+0.5597
P-glycoprotein substrateSubstrate0.54
P-glycoprotein inhibitor INon-inhibitor0.5574
P-glycoprotein inhibitor IINon-inhibitor0.9828
Renal organic cation transporterNon-inhibitor0.9052
CYP450 2C9 substrateNon-substrate0.8508
CYP450 2D6 substrateNon-substrate0.8947
CYP450 3A4 substrateNon-substrate0.5262
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8384
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8344
BiodegradationReady biodegradable0.6545
Rat acute toxicity2.4505 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9228
hERG inhibition (predictor II)Non-inhibitor0.9044
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0690000000-f598b8bee69a6b62e817
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fb9-2930000000-143e32f52c12761e81dd

Taxonomy

Description
This compound belongs to the class of organic compounds known as chlorophenoxyacetates. These are compounds containing a phenoxyacetate that carries one or more chlorine atoms on the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxyacetic acid derivatives
Direct Parent
Chlorophenoxyacetates
Alternative Parents
Butyrophenones / Aryl ketones / Benzoyl derivatives / Dichlorobenzenes / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / Alpha-branched alpha,beta-unsaturated ketones / Aryl chlorides / Enones
show 7 more
Substituents
Chlorophenoxyacetate / Butyrophenone / 1,2-dichlorobenzene / Phenoxy compound / Benzoyl / Phenol ether / Aryl ketone / Halobenzene / Chlorobenzene / Alkyl aryl ether
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, monocarboxylic acid, dichlorobenzene, aromatic ketone (CHEBI:4876)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Bowes TJ, Gupta RS: Induction of mitochondrial fusion by cysteine-alkylators ethacrynic acid and N-ethylmaleimide. J Cell Physiol. 2005 Mar;202(3):796-804. [PubMed:15389563]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Ronquist G, Agren GK: A Mg2+- and Ca2+-stimulated adenosine triphosphatase at the outer surface of Ehrlich ascites tumor cells. Cancer Res. 1975 Jun;35(6):1402-6. [PubMed:124205]
  2. Proverbio F, Condrescu-Guidi M, Whittembury G: Ouabain-insensitive Na+ stimulation of an Mg-2+ -dependent ATPase in kidney tissue. Biochim Biophys Acta. 1975 Jun 25;394(2):281-92. [PubMed:124600]
  3. Valdes RM, Huff MO, El-Masri MA, El-Mallakh RS: Effect of ethacrynic acid on sodium pump alpha isoforms in SH-SY5Y cells. Bipolar Disord. 2003 Apr;5(2):123-8. [PubMed:12680902]
  4. Kiil F, Sejersted OM: Analysis of energy metabolism and mechanism of loop diuretics in the thick ascending limb of Henle's loop in dog kidneys. Acta Physiol Scand. 2003 May;178(1):73-82. [PubMed:12713517]
  5. Schurek HJ, Aulbert E, Ebel H, Muller-Suur C: Influence of ouabain and ethacrynic acid on sodium transport and NaK-ATPase activity in the isolated perfused rat kidney. Curr Probl Clin Biochem. 1975;4:162-8. [PubMed:127690]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Participates in the Wnt signaling pathway. Activates transcription of target genes in the presence of CTNNB1 and EP300. May play a role in hair cell differentiation and follicle morphogenesis. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by LEF1 and CTNNB1. Regulates T-cell receptor alpha enhancer function. Binds DNA in a sequence-specific manner. PIAG antagonizes both Wnt-dependent and Wnt-independent activation by LEF1 (By similarity). Isoform 3 lacks the CTNNB1 interaction domain and may be an antagonist for Wnt signaling. Isoform 5 transcriptionally activates the fibronectin promoter, binds to and represses transcription from the E-cadherin promoter in a CTNNB1-independent manner, and is involved in reducing cellular aggregation and increasing cell migration of pancreatic cancer cells. Isoform 1 transcriptionally activates MYC and CCND1 expression and enhances proliferation of pancreatic tumor cells.
Specific Function
Armadillo repeat domain binding
Gene Name
LEF1
Uniprot ID
Q9UJU2
Uniprot Name
Lymphoid enhancer-binding factor 1
Molecular Weight
44200.41 Da
References
  1. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ, Carson DA: Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One. 2009 Dec 14;4(12):e8294. doi: 10.1371/journal.pone.0008294. [PubMed:20011538]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. van Iersel ML, Ploemen JP, Lo Bello M, Federici G, van Bladeren PJ: Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact. 1997 Dec 12;108(1-2):67-78. [PubMed:9463521]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Glutathione transferase activity
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name
GSTA2
Uniprot ID
P09210
Uniprot Name
Glutathione S-transferase A2
Molecular Weight
25663.675 Da
References
  1. Depeille P, Cuq P, Passagne I, Evrard A, Vian L: Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer. 2005 Jul 25;93(2):216-23. [PubMed:15999103]
  2. Awasthi S, Srivastava SK, Ahmad F, Ahmad H, Ansari GA: Interactions of glutathione S-transferase-pi with ethacrynic acid and its glutathione conjugate. Biochim Biophys Acta. 1993 Jul 10;1164(2):173-8. [PubMed:8329448]
  3. Iersel ML, Ploemen JP, Struik I, van Amersfoort C, Keyzer AE, Schefferlie JG, van Bladeren PJ: Inhibition of glutathione S-transferase activity in human melanoma cells by alpha,beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem Biol Interact. 1996 Oct 21;102(2):117-32. [PubMed:8950226]
  4. van Iersel ML, Ploemen JP, Lo Bello M, Federici G, van Bladeren PJ: Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact. 1997 Dec 12;108(1-2):67-78. [PubMed:9463521]
  5. Morrow CS, Smitherman PK, Townsend AJ: Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Biochem Pharmacol. 1998 Oct 15;56(8):1013-21. [PubMed:9776312]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bertucci C, Nanni B, Raffaelli A, Salvadori P: Chemical modification of human albumin at cys34 by ethacrynic acid: structural characterisation and binding properties. J Pharm Biomed Anal. 1998 Oct;18(1-2):127-36. [PubMed:9863950]
  2. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312]
  3. Fehske KJ, Muller WE: High-affinity binding of ethacrynic acid is mediated by the two most important drug binding sites of human serum albumin. Pharmacology. 1986;32(4):208-13. [PubMed:3714803]
  4. Lebedev AA, Samokrutova OV: [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence]. Farmakol Toksikol. 1989 May-Jun;52(3):40-3. [PubMed:2792351]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997 Jul 25;272(30):18526-9. [PubMed:9228014]

Drug created on June 13, 2005 07:24 / Updated on January 23, 2018 12:14